Prof. Michael Schlander

Prof. Michael Schlander

Prof. Michael Schlander

Position:

Head of Division

Phone:

+49 6221 42-1910

Fax:

+49 6221 42-1919

Michael Schlander is a full professor of health economics at the University of Heidelberg. Adhering to the Jülich model, he has been granted leave of absence to act as founding Head of the Division of Health Economics at the DKFZ (since 2017). He is also the founding chairman of the not-for-profit INNOVAL (Institute for Innovation & Valuation in Health Care) in Wiesbaden (since 2005). In 2008, he was a co-founder of the German Society for Health Economics, and in 2012, he acted as scientific chair for the European ISPOR Congress in Berlin, which had more than 3,500 attendants.

Professor Schlander studied medicine and psychology at the University of Frankfurt and has been licensed as a physician in Germany since 1985. He received his M.D. (summa cum laude) from the University of Frankfurt, his M.B.A. (as valedictorian of the class of 1994) from City University of Seattle, Washington, a diploma in health economics from the Stockholm School of Economics (2002), and the venia legendi for health economics from the University of Heidelberg (2007).

Prior to returning to academia in 2002, he had spent 15 years in executive roles in the international biopharmaceutical industry in Belgium, Germany, Switzerland, and the United States. For further information, please refer to www.michaelschlander.com. 

 

Selected Publications

J. Richardson, M. Schlander:
Health Technology Assessment (HTA) and economic evaluation: efficiency or fairness first.
Journal of Market Access & Health Policy, (2019) 7(1) 1-12.
DOI: 10.1080/20016689.2018.1557981.

J. J. Caro, J.E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:
Determining value in Health Technology Assessment: Stay the course or tack away?  
PharmacoEconomics, (2019) 37(3) 293-299.
DOI: 10.1007/s40273-018-0742-2.

M. Schlander, M., C.C. Adarkwah, A. Gandjour:
Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
Expert Review of Pharmacoeconomics & Outcomes Research, (2015) 15(1) 171-179.

M. Schlander, S. Garattini, S. Holm, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.
Journal of Comparative Effectiveness Research, (2014) 3(4) 399-422.

to top